Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:8/23/2018
Start Date:August 17, 2018
End Date:December 31, 2019

Use our guide to learn which trials are right for you!

Evaluation of Hyperpolarized 129Xe MRI as Compared to 133Xe Scintigraphy for the Assessment of Pulmonary Function in Patients Being Evaluated for Possible Lung Resection Surgery

This study compares the equivalence of hyperpolarized 129Xe MRI as compared to 133Xe
scintigraphy for the evaluation of pulmonary function in patients being evaluated for lung
resection.

This is a multicenter, randomized, open-label, cross-over Phase 3 study evaluating
hyperpolarized 129Xe gas MRI as compared to 133Xe scintigraphy for the evaluation of
pulmonary function. This study will enroll subjects being evaluated for possible lung
resection surgery (i.e. segmentectomy, lobectomy, or pneumonectomy). Subjects will have both
a 129Xe MRI and 133Xe scintigraphy image. The vast differences in technique for obtaining
hyperpolarized 129Xe MRI as compared to 133Xe scintigraphy make it impossible to blind study
procedures. However, all image interpretation will be performed by personnel blinded to the
subject's medical history and all study assessments.

Inclusion Criteria:

1. Male or female subjects ≥18 years of age.

2. Subject is being evaluated for possible lung resection (e.g., segmentectomy,
lobectomy, or pneumonectomy).

3. Subject is able to undergo MRI imaging and able to fit in the MRI coil.

4. Subject is willing and able to comply with all study procedures.

5. Subject must understand and voluntarily sign an informed consent form (ICF) prior to
any study specific assessments or procedures.

Exclusion Criteria:

1. Baseline blood oxygen saturation (SpO2) <90% at rest. For patients requiring routine
supplemental oxygen, SpO2 measurements should be taken with the patient's normal
oxygen supplementation.

2. Female subjects of childbearing potential with a positive serum pregnancy test at
screening, or who are not taking (or not willing to take) acceptable birth control
measures through the Follow-up Period. Adequate birth control methods include with a
monogamous partner who was sterilized more than 6 months prior to screening, or
measures with a Pearl index of <1 used consistently and correctly (including
intrauterine devices, or implantable, injectable, oral, or transdermal
contraceptives). Women are not considered to be of childbearing potential if they meet
at least 1 of the following 2 criteria as documented by the Investigator:

- They have had a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy
at a minimum of 1 menstrual cycle prior to signing the ICF; or

- They are post-menopausal: for women ≥55 years of age, defined as ≥1 year since
their last menstrual period, or for women <55 years of age, defined as ≥1 year
since their last menstrual period and have a follicle-stimulating hormone (FSH)
level in the laboratory's normal range for post-menopausal phase.

3. Women who are lactating and insist on breast feeding.

4. Subjects who have received any other investigational therapy within 4 weeks prior to
Screening.

5. Subjects who require anesthesia or heavy sedation to undergo MRI testing. Mild
sedation could be acceptable (i.e. a low dose oral acting anxiolytic medication such
as alprazolam) as long as, in the opinion of the investigator, the subject meets
Inclusion Criteria #4 and #5.
We found this trial at
2
sites
Durham, North Carolina 27705
Principal Investigator: Matthew Hartwig, MD
Phone: 919-668-5499
?
mi
from
Durham, NC
Click here to add this to my saved trials
Charlottesville, Virginia 22903
(434) 924-0311
Principal Investigator: Michael Shim, MD
Phone: 319-759-9578
University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials